Zealand Pharma shares drop 32% on obesity drug data
Zealand Pharma’s shares plummeted by a record 32% following disappointing data from a Phase 2 trial of its obesity drug, petrelintide, which was tested on overweight and obesity patients without type 2 diabetes. The company […]
